Phase I/II Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers



Status:Archived
Conditions:Lung Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:November 2008
End Date:December 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Phase I/II Study of LBH589 in Combination With Erlotinib for Advanced Aerodigestive Tract Cancers (CLBH5889CUS11T)


The purpose of the study is to:

- Find out if Erlotinib and LBH589 can be safely given together in patients with advanced
non-small cell lung cancer (NSCLC) or Head and Neck (H&N) Cancer.

- Learn more about the side effects of these two drugs when combined together.

- Learn how these two drugs work in cancer cells when they are combined.

- Learn how this combination affects the ways in which they are absorbed by the body and
eliminated.

- Find the highest doses of Erlotinib and LBH589 that can be safely given without causing
serious side effects.


Patients will be asked to remain on the study for a minimum of 3 months unless the study
doctor decides the patient should be taken off the study or the patient withdraws from the
study. Each cycle of treatment is 21 days in length and there is a 30 day follow-up after
the patient receives their last dose of study drug. Scans will be repeated to see how their
cancer is doing after two cycles of treatment. These scans wil be repeated every 2 cycles
for the first six cycles and then every 3 cycles for as long as the patient remains on the
study. The patient may continue on therapy as long as they are responding or have stable
disease.


We found this trial at
1
site
H. Lee Moffitt Cancer Center & Research Institute
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials